Objective: People living close to an environmental hazard site may suffer health harms from real or perceived contaminant exposures. In class-action litigation, medical monitoring is a potential remedy that has been allowed in some jurisdictions but not others. From 1952 to 1989, a US Department of Energy uranium metal plant near Fernald, Ohio, released ionizing radiation and uranium particulates into the surrounding community.
Methods: Settlement of litigation between nearby residents and the Department of Energy resulted in an 18-year medical monitoring program (N = 9775), which focused on general health promotion rather than effects of uranium.
Results: Participation was higher than projected; decreases in common risk factors (cholesterol and blood pressure) and deaths from cancer have been observed.
Conclusions: These data support the appropriateness of comprehensive medical monitoring as a remedy for people affected by defined sources of environmental contaminants.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868344 | PMC |
| http://dx.doi.org/10.1097/JOM.0b013e3181c558f1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retraction Note: Intraoperative neurophysiological monitoring: a vital tool for surgical precision and patient safety.
Neurosurg Rev
January 2025
Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education & Research, Sawangi, Meghe, Wardha, India.
Effects of denosumab and zoledronic acid on postmenopausal osteoporosis, bone density, and fat-free mass.
Arch Osteoporos
January 2025
Division of Endocrinology & Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Unlabelled: This study compared denosumab and zoledronic acid for treating osteoporosis in drug-naïve postmenopausal Korean women. Over 3 years, both drugs significantly increased bone mineral density. However, denosumab also improved fat-free mass, suggesting it may be a better initial treatment for osteoporosis with low muscle mass, assuming all other conditions remain constant.
View Article and Find Full Text PDFPharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System.
Int J Clin Pharm
January 2025
Department of Pharmacy, Medical Supplies Center of Chinese, PLA General Hospital, 28 Fu Xing Road, Beijing, 100853, China.
Background: Drug-induced hypofibrinogenemia has received increasing scrutiny; however, the specific drugs involved remain poorly characterized. Hypofibrinogenemia can have significant clinical implications, including increased bleeding risks.
Aim: This study aimed to utilize the FDA Adverse Event Reporting System (FAERS) to identify and analyze drugs frequently implicated in drug-induced hypofibrinogenemia.
Retraction Note: Visual electrophysiologic monitoring of traumatic optic neuropathies requiring neurosurgical interventions.
Neurosurg Rev
January 2025
Department of Physiology, Mahatma Gandhi Institute of Medical Sciences, Wardha, Maharashtra, India.
Comparison of continuous glucose monitoring with self-monitoring of blood glucose in type 1 diabetes in the changing atmospheric pressures in aviation: a hypobaric flight simulation.
Diabetologia
January 2025
Department of Diabetes and Endocrinology, Medical University of Graz, Graz, Austria.
Aim/hypothesis: Pilots with type 1 diabetes are required to perform capillary glucose monitoring regularly during flights. Continuous glucose monitoring (CGM) may be an effective and more practical alternative. This study aimed to assess the accuracy of CGM systems against self-monitoring of blood glucose (SMBG) during a hypobaric flight simulation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!